Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shexiang Baoxin Pill for ischemia with non-obstructive coronary artery disease (INOCA)
ChiCTR2400080152Phase 4Recruiting
- Sponsor
- Gansu Provincial People's Hospital
- Start
- Jan 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in non-obstructive coronary artery disease comparing Shexiang Baoxin Pill + conventional therapy with Placebo + conventional therapy (2 arms). Primary endpoint: Coronary flow reserve. Started Jan 2024; status: recruiting.
02
Drugs
Shexiang Baoxin Pill
03
Conditions
non-obstructive coronary artery disease
Beyond the preview
Go deeper on ChiCTR2400080152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080152.